FYARRO® sales of $7.2 million for Q3 2024, reflecting 21% year over year sales growth

Aadi continues to focus on FYARRO commercial business and comprehensive strategic review to maximize shareholder value

LOS ANGELES, Nov. 6, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced financial results for the third quarter ended September 30, 2024, and provided recent corporate progress.

"The third quarter saw strong sales growth for FYARRO, backed by continued account momentum, increased demand and a nearly 90 percent reorder rate – all reinforcing the clinical value of FYARRO for patients with advanced malignant PEComa," said Dave Lennon, President and CEO of Aadi Bioscience. "Our comprehensive review of strategic options to maximize value for shareholders is ongoing, and we will provide further updates when available."

Recent Operational Highlights

  • FYARRO net product sales were $7.2 million in the third quarter, an increase of 17 percent from Q2 2024 and 21 percent compared to the prior-year period. This increase is primarily driven by continued momentum from top accounts and strong demand.
  • Aadi completing wind-down of the PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. All patients who were still receiving benefit at the time the study was halted were transitioned to an expanded access protocol, and a report out of the PRECISION1 trial is expected to be provided in 2025.
  • The Phase 2 trials of nab-sirolimus for advanced or recurrent endometrioid-type endometrial cancer (EEC) and neuroendocrine tumors (NETs) enrolled 24 and 12 patients, respectively. Both studies enrolled sufficient patients to assess initial efficacy signals later this year.
  • Aadi remains actively engaged in a comprehensive strategic review to maximize shareholder value. Aadi has not provided a specific timeline to complete this process and will provide further updates when appropriate.

Third Quarter 2024 Financial Results

  • Cash, cash equivalents and short-term investments as of September 30, 2024, were $62.6 million as compared to $108.8 million as of December 31, 2023, which is expected to fund operations into at least 2H 2026 based on current plans.
  • Total revenue for the quarter ended September 30, 2024, was $7.2 million, resulting from sales of FYARRO.
  • Operating expenses for the third quarter September 30, 2024, were $20.6 million as compared to $23.8 million in the prior year quarter and included $2.6 million of restructuring expenses.
  • Net loss for the three months ended September 30, 2024, was $12.5 million as compared to $16.3 million for the three months ended September 30, 2023.

About Aadi Bioscience 

Aadi is a precision oncology company focused on the commercialization of FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains certain forward-looking statements regarding the business of Aadi Bioscience that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to: the Company's cash runway extending into at least the second half of 2026; the Company's ongoing strategic review; the anticipated timing of data releases and reports of the Company's clinical trials; and the sufficiency of the Company's existing capital resources and the expected timeframe to fund the Company's future operating expenses and capital expenditure requirements. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks associated with the ability to successfully commercialize FYARRO; risks related to successfully identifying strategic options and implementing such options as part of the Company's ongoing strategic review; and risks related to the Company's estimates regarding future expenses, capital requirements and need for additional financing.

Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including under the caption "Item 1A. Risk Factors," and in Aadi's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Aadi's reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at www.sec.gov.

All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:
IR@aadibio.com

 

AADI BIOSCIENCE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)








September 30,


December 31,



2024


2023

Assets




Current assets:





Cash and cash equivalents

$             30,537


$           62,888


Short-term investments

32,082


45,957


Accounts receivable, net

6,540


5,488


Inventory

5,468


6,427


Prepaid expenses and other current assets

2,688


3,826

Total current assets

77,315


124,586

Property and equipment, net

5,982


4,802

Operating lease right-of-use assets

886


1,169

Other assets

1,515


1,866

Total assets

$             85,698


$         132,423





Liabilities and stockholders' equity




Current liabilities:





Accounts payable

$               1,374


$             5,898


Accrued liabilities

14,117


14,306


Operating lease liabilities, current portion

322


434


Due to licensor payable

-


5,757

Total current liabilities

15,813


26,395

Operating lease liabilities, net of current portion

624


833

Other liabilities

393


-

Total liabilities

16,830


27,228

Stockholders' equity:





Common stock

2


2


Additional paid-in capital

383,208


374,129


Accumulated other comprehensive income

39


27


Accumulated deficit

(314,381)


(268,963)

Total stockholders' equity 

68,868


105,195

Total liabilities and stockholders' equity

$             85,698


$        132,423

 

AADI BIOSCIENCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share data and earnings per share amounts)

(Unaudited)












Three months ended


Nine months ended



September 30,


September 30,



2024


2023


2024


2023

Revenue






Product sales, net


$        7,212


$        5,959


$         18,744


$         18,028

Total Revenue


7,212


5,959


18,744


18,028

Operating expenses










Selling, general and administrative


7,186


11,221


25,698


34,204


Research and development


9,997


11,890


36,683


36,161


Restructuring charges


2,638


-


2,638


-


Cost of goods sold


804


697


2,234


1,882

Total operating expenses


20,625


23,808


67,253


72,247

Loss from operations


(13,413)


(17,849)


(48,509)


(54,219)

Other income (expense)










Foreign exchange loss


(1)


-


(4)


(3)


Interest income


906


1,605


3,249


4,900


Interest expense


(38)


(58)


(154)


(174)

Total other income (expense), net


867


1,547


3,091


4,723

Net loss


$     (12,546)


$     (16,302)


$        (45,418)


$        (49,496)










Net loss per share, basic and diluted


$         (0.46)


$         (0.60)


$            (1.68)


$            (1.84)










Weighted average number of common shares outstanding, basic and diluted


27,041,327


26,946,683


27,010,791


26,901,810

 

(PRNewsfoto/Aadi Bioscience)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-announces-financial-results-for-the-third-quarter-2024-and-provides-corporate-update-302297102.html

SOURCE Aadi Bioscience

Copyright 2024 PR Newswire

Aadi Bioscience (NASDAQ:AADI)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Aadi Bioscience.
Aadi Bioscience (NASDAQ:AADI)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Aadi Bioscience.